Indeed, it was reported that treatment with the phospholipid dilauroyl phosphatidylcholine protected mice from the development of MASLD and insulin resistance through LRH-1–dependent mechanisms because the protective effects of dilauroyl phosphatidylcholine were lost in LRH-1-/- mice.27 The gene discussed is NR5A2; the disease is metabolic dysfunction-associated steatotic liver disease.